List of Excipients in Branded Drug FLUDEOXYGLUCOSE F 18

Generic Drugs Containing FLUDEOXYGLUCOSE F 18

Company	Ingredient	NDC	Excipient
UIHC-P E T IMAGING CENTER	fludeoxyglucose f-18	24417-001	SODIUM CHLORIDE
UIHC-P E T IMAGING CENTER	fludeoxyglucose f-18	24417-001	SODIUM CITRATE
NCM-USA Bronx LLC	fludeoxyglucose f 18	24445-334	ALCOHOL
NCM-USA Bronx LLC	fludeoxyglucose f 18	24445-334	SODIUM CHLORIDE
NCM-USA Bronx LLC	fludeoxyglucose f 18	24445-334	SODIUM CITRATE

What are the Most Frequently-Used Excipients in FLUDEOXYGLUCOSE F 18?

# Of NDCs	Excipient
6	ALCOHOL
14	SODIUM CHLORIDE
8	SODIUM CITRATE
1	TRISODIUM CITRATE DIHYDRATE

Fludeoxyglucose F 18 Excipient Strategy and Commercial Opportunities

Last updated: August 23, 2026

Fludeoxyglucose F 18, commonly called FDG F 18 or [18F]FDG, is a short-lived PET radiopharmaceutical with limited excipient complexity and high operational sensitivity. Its commercial value is driven less by formulation differentiation than by cyclotron access, synthesis reliability, sterility assurance, quality control, delivery radius, reimbursement, and scanner utilization.

The active ingredient has a physical half-life of approximately 109.8 minutes. That decay profile constrains manufacturing, release testing, transportation, inventory, and geographic expansion.[1] A successful excipient strategy therefore prioritizes radiochemical stability, low toxicity, rapid release, and compatibility with automated synthesis systems rather than differentiated oral or depot delivery.

What excipients are used in fludeoxyglucose F 18 injection?

Commercial FDG F 18 injection is generally a sterile aqueous solution containing 2-deoxy-2-[18F]fluoro-D-glucose, sodium chloride, and water for injection. Product labels typically specify a controlled pH range and do not rely on antimicrobial preservatives.[2]

Component	Strategic function	Commercial relevance
2-deoxy-2-[18F]fluoro-D-glucose	PET imaging active ingredient	Radioactive decay makes same-day production necessary
Sodium chloride	Tonicity adjustment and injectable vehicle support	Low-cost, familiar, and compatible with IV administration
Water for injection	Primary solvent	Must meet pharmaceutical water and microbial-quality requirements
pH adjustment system, where applicable	Maintains product pH within label specifications	Can affect stability, compatibility, and regulatory comparability
Residual synthesis solvents and reagents	Process-related materials, not intended formulation excipients	Controlled through validated purification and quality testing

FDG products are typically supplied as preservative-free, single-use or pharmacy-prepared injections. Label composition varies by manufacturer and presentation. Some products may have formulation or process differences that are not commercially meaningful to the end user but remain important for chemistry, manufacturing, and controls documentation.

The principal formulation target is a sterile, injectable solution with acceptable radiochemical purity, radionuclidic identity, chemical purity, pH, endotoxin level, sterility, and visual appearance. USP standards and FDA radiopharmaceutical guidance are central to the control strategy.[3,4]

How does the short half-life affect FDG excipient selection?

The 109.8-minute half-life makes FDG a time-critical product. Excipients must support product quality during synthesis, release testing, transport, administration, and residual decay without creating additional manufacturing or regulatory burdens.

Radiolysis and chemical stability

Ionizing radiation can generate reactive species in aqueous solutions. Potential consequences include radiochemical impurities, degradation of the glucose analogue, changes in pH, and increased radiolysis products during storage or shipment.

A formulation developer may evaluate:

• Buffer selection and concentration
• Dissolved oxygen
• Trace metals
• Container interaction
• Radiation dose rate
• Product concentration
• Time from end of synthesis to administration

Antioxidants or radical scavengers may theoretically reduce radiolysis, but their use creates new requirements. The excipient must be safe for intravenous administration, compatible with the synthesis process, included in the specification strategy, and justified in the regulatory submission. A stabilizer that improves radiochemical purity but complicates validation may have limited commercial value.

Compatibility with automated synthesis

Most FDG is manufactured through automated radiosynthesis modules using fluorine-18 produced by a cyclotron. Excipients must not interfere with precursor reactions, hydrolysis, purification, cartridge performance, sterile filtration, or final-product testing.

A formulation that requires additional mixing or post-synthesis manipulation can reduce batch throughput and increase operator exposure. The preferred approach is usually a low-excipient formulation that can be integrated into a closed or functionally closed manufacturing process.

Release-time constraints

Every additional test affects usable shelf life. FDG facilities commonly perform rapid release testing for identity, radiochemical purity, pH, residual solvents, endotoxins, and appearance. Sterility testing is completed post-release under applicable regulatory controls.

An excipient strategy that introduces difficult-to-test impurities or complex assay requirements can materially reduce the commercial delivery window. This is especially important for facilities serving hospitals more than a few hours from the production site.

What formulation patents protect fludeoxyglucose F 18?

FDG F 18 has limited composition-of-matter differentiation because the active ingredient and basic injectable presentation have been established for decades. The most commercially relevant IP is more likely to involve manufacturing processes, synthesis modules, precursor chemistry, purification, quality-control systems, or logistics than a basic sodium-chloride-and-water formulation.

IP category	Likely commercial value	FDG relevance
Active ingredient composition	Low	Established radiolabeled glucose analogue
Basic aqueous formulation	Low	Simple formulation is widely reproducible
Buffer or stabilizer system	Low to moderate	Value depends on demonstrated radiochemical or shelf-life improvement
Radiosynthesis process	Moderate to high	Can improve yield, reliability, automation, or cycle time
Purification and cartridge technology	Moderate to high	May reduce impurities and production failures
Automated synthesis hardware and software	Moderate to high	Supports reproducibility and labor efficiency
Distribution and scheduling systems	Usually trade-secret value	Critical because of radioactive decay
Manufacturing know-how	High operational value	Often more important than enforceable formulation patents

A current patentability or freedom-to-operate conclusion cannot be inferred from the product label. Patent ownership may involve universities, cyclotron manufacturers, synthesis-platform suppliers, hospital systems, or radiopharmacy operators. Patent families also differ by jurisdiction and may have expired, lapsed, or been narrowed through prosecution.

For commercial diligence, the key question is whether a claimed process is necessary for economic FDG production. A technically valid patent with multiple noninfringing alternatives may have limited blocking power.

What is the FDA regulatory status of FDG F 18?

FDG F 18 is an FDA-approved PET diagnostic radiopharmaceutical used in oncology, cardiology, and neurology. FDA-recognized applications include assessment of glucose metabolism in suspected or known malignancy, myocardial viability, and abnormal brain metabolism in selected clinical settings.[2,5]

The product is regulated as a prescription drug and must meet requirements for:

• Drug substance and finished-product manufacturing
• Sterility assurance
• Endotoxin control
• Radiochemical and radionuclidic purity
• Identity and assay
• Container closure integrity
• Environmental and personnel controls
• Radiation safety
• Distribution and recordkeeping

PET drug manufacturing is subject to specialized FDA expectations because of the short half-life, on-site or regional production model, and reliance on automated synthesis equipment. FDA’s PET drug current good manufacturing practice framework addresses production, quality control, facilities, equipment, and release procedures.[4]

What is the Orange Book status of fludeoxyglucose F 18?

The Orange Book is relevant for approved drug products and patent or exclusivity listings, but it is not a complete map of every commercial barrier affecting a radiopharmaceutical. FDG’s practical competitive barriers are primarily operational.

The basic FDG injection market generally lacks the conventional small-molecule exclusivity profile associated with a recently approved branded drug. The active ingredient is mature, and competition typically occurs among approved manufacturers, outsourcing facilities, hospital pharmacies, and radiopharmacy networks.

Any product-specific Orange Book patent listing, reference product designation, or regulatory exclusivity should be verified against the current FDA database and the relevant application number. A label comparison alone does not establish whether a manufacturer has listed process, formulation, or method-of-use patents.

When does fludeoxyglucose F 18 lose exclusivity?

FDG’s primary market exclusivity has effectively expired as a commercial concept because the active ingredient and clinical use are established. The relevant commercial question is not a single patent expiration date but whether a supplier can maintain an economically defensible production and distribution network.

Exclusivity or barrier	Current strategic importance
Active-ingredient exclusivity	Minimal
Basic formulation exclusivity	Minimal
New-drug exclusivity	Generally not the principal barrier
Method-of-use patents	Potentially relevant for narrow imaging indications
Manufacturing patents	Relevant if process claims are difficult to design around
Equipment or software rights	Relevant to specific production platforms
Trade secrets	High operational importance
Cyclotron and radiopharmacy footprint	High commercial importance
Hospital contracts and scheduling integration	High commercial importance

FDG does not face a biosimilar pathway because it is a radioactive small-molecule diagnostic, not a biologic. Competitive entry is more likely to occur through an abbreviated or alternative approved product pathway, compounding or outsourcing arrangements where legally permitted, or a new manufacturer obtaining its own regulatory authorization.

Which companies are competing in the FDG F 18 market?

Competition is fragmented by geography. Major participants include large radiopharmacy operators, nuclear medicine suppliers, hospital-based cyclotron programs, and regional PET drug manufacturers. Examples of companies active in PET radiopharmaceutical production or distribution have included Cardinal Health, Curium, Jubilant Radiopharma, SOFIE, and other regional operators, subject to market, facility, and product-specific changes.

The competitive unit is usually the production site rather than the corporate parent. A supplier with a strong national brand may still rely on local cyclotrons and regional delivery hubs.

What determines commercial share?

FDG market share is shaped by:

• Number and location of cyclotrons
• Daily synthesis capacity
• Availability of automated modules
• Batch failure rate
• Delivery radius
• PET/CT and PET/MRI site density
• Hospital and imaging-center contracts
• Insurance coverage and reimbursement
• Ability to produce on weekends and holidays
• Reliability during cyclotron downtime
• Capacity to support oncology, neurology, and cardiac demand

Because the product decays continuously, a facility closer to the customer can compete effectively against a larger producer located farther away.

What excipient innovation opportunities exist for FDG?

The largest opportunities are incremental and operational rather than transformational.

Radiolysis-control formulations

A stabilizing excipient system could extend the usable quality window or reduce radiochemical impurity formation. Commercial value would depend on measurable gains such as:

• Longer post-production usability
• Lower repeat-production rates
• Greater delivery radius
• Reduced batch rejection
• Improved performance at higher activity concentrations

The regulatory burden rises if the new excipient changes toxicity, impurity profiles, injection tolerability, or validated release methods.

Low-volume, high-activity presentations

High-activity formulations may reduce injection volume and improve dose preparation. This could benefit high-throughput radiopharmacies and hospitals with automated dispensing systems. The formulation must maintain homogeneity, sterility, container compatibility, and accurate dose calibration.

Ready-to-use unit doses

Unit-dose products can reduce pharmacy labor and preparation errors. The commercial benefit depends on local dispensing rules, decay during transport, dose flexibility, and the ability to meet site-specific appointment schedules.

Container-closure improvements

Low-adsorption vials, syringes, and shielded delivery systems can reduce activity loss and improve handling. Packaging is not technically an excipient, but it can produce meaningful commercial differentiation. Container systems must be evaluated for extractables, leachables, adsorption, radiation resistance, and dose measurement accuracy.

Multi-isotope platform compatibility

A formulation and manufacturing platform that supports FDG alongside other PET agents may improve asset utilization. The value lies in shared cyclotron capacity, cleanroom infrastructure, quality systems, and delivery networks.

What manufacturing and IP barriers affect FDG entry?

Entry requires more than access to fluorine-18. A commercially viable supplier must establish a qualified cyclotron, automated synthesis system, pharmaceutical-grade facility, validated analytical methods, trained staff, radiation controls, sterility systems, and a distribution model that accounts for decay.

Critical manufacturing barriers include:

1. Reliable fluorine-18 production.
2. Consistent precursor and reagent supply.
3. Automated synthesis reproducibility.
4. Rapid radiochemical purity testing.
5. Validated sterile filtration.
6. Low endotoxin performance.
7. Cyclotron uptime and preventive maintenance.
8. Backup production capacity.
9. Route and traffic planning.
10. Regulatory inspection readiness.

Patent barriers may arise from proprietary synthesis modules, cassette designs, precursor preparation, purification cartridges, or software. In many cases, trade secrets and equipment dependence impose greater practical constraints than composition patents.

What patent litigation and Paragraph IV risks affect FDG?

FDG is unlikely to generate the same level of Paragraph IV litigation as a recently launched branded medicine. The basic active ingredient is mature, and the commercial market has multiple suppliers.

Potential disputes could still involve:

• A proprietary radiosynthesis route
• A precursor or labeling chemistry
• An automated synthesis cassette
• A purification method
• A method of use for a specific diagnostic indication
• A container or dispensing system
• Contractual restrictions involving equipment or software

A Paragraph IV challenge would be commercially meaningful only if the challenged patent materially constrained market entry. A narrow patent covering a nonessential manufacturing route would have limited impact because an entrant could use a different validated process.

No biosimilar litigation pathway applies. Generic-entry risk is better assessed through application type, approved labeling, manufacturing capability, and facility geography than through biologic interchangeability concepts.

How does FDG compare with newer PET radiopharmaceuticals?

FDG has a simpler commercial and formulation profile than many newer PET products. Its main advantages are clinical familiarity, broad demand, established reimbursement, and extensive manufacturing experience.

Factor	FDG F 18	Newer targeted PET agents
Clinical use	Broad oncology, cardiac, and neurologic applications	Often narrower disease or biomarker populations
Formulation complexity	Usually low	May require specialized ligands, chelators, buffers, or kits
Supply model	Mature regional network	More concentrated and indication-specific
Patent protection	Generally limited for basic product	Often stronger composition and method-of-use protection
Manufacturing risk	High operational sensitivity	May include more complex chemistry and raw-material dependence
Commercial differentiation	Delivery, quality, price, reliability	Clinical utility, labeling, IP, and supply
Generic or competitor entry	Relatively accessible	Often constrained by active patents and specialized manufacturing

FDG is therefore a scale-and-logistics business. Newer PET agents are more likely to be an IP-and-clinical-differentiation business.

What revenue exposure and commercial scenarios should investors assess?

Public company reporting rarely isolates FDG revenue cleanly. Revenue exposure is often included within nuclear medicine, radiopharmacy, imaging, or pharmaceutical services segments.

Three commercial scenarios are most relevant:

Base case: regional supply competition

Margins depend on delivery density, production yield, staffing, and contract retention. Price competition is strongest in markets with multiple nearby cyclotrons.

Upside case: decentralized PET expansion

Growth in PET/CT capacity, oncology imaging, and regional cancer networks can increase FDG demand. The strongest beneficiaries are suppliers that can add production nodes without materially increasing quality overhead.

Downside case: capacity and reimbursement pressure

Cyclotron outages, labor shortages, reimbursement reductions, hospital insourcing, and competition from nearby producers can reduce utilization and pricing. Because FDG cannot be stored for long periods, excess production has limited salvage value.

Key Takeaways

• FDG F 18 uses a deliberately simple injectable formulation, generally based on the active ingredient, sodium chloride, and water for injection.
• Excipient innovation is commercially attractive only if it improves radiochemical stability, delivery radius, release timing, or batch reliability.
• The active ingredient has little practical composition-patent differentiation compared with newer PET agents.
• FDG has no biosimilar pathway; competitive entry is driven by drug approval, facility capability, and regional logistics.
• The 109.8-minute half-life makes cyclotron location, production uptime, quality testing, and route planning central commercial assets.
• Manufacturing know-how, automated synthesis systems, purification methods, and distribution contracts may be more valuable than basic formulation patents.
• The strongest commercial opportunities are regional radiopharmacy expansion, unit-dose delivery, low-loss packaging, radiolysis control, and multi-isotope production platforms.
• Patent and Paragraph IV risk is generally lower than for newer targeted radiopharmaceuticals, but process and method-of-use disputes can still affect specific products.

FAQs about fludeoxyglucose F 18 excipients and commercial opportunities

Is FDG F 18 preservative-free?

Most commercial FDG F 18 injections are supplied without antimicrobial preservatives. The exact composition must be confirmed in the applicable manufacturer label.

Can antioxidants be added to FDG F 18?

Potentially, but any antioxidant would require evaluation for intravenous safety, radiochemical compatibility, residual impurities, release testing, and regulatory approval. A stabilizer is commercially useful only if it produces measurable quality or delivery benefits.

Does FDG F 18 have a biosimilar competitor?

No. FDG F 18 is a radioactive small-molecule diagnostic and is not regulated through the biosimilar pathway.

What is the most important competitive advantage in FDG manufacturing?

Reliable regional production and delivery are usually more important than formulation complexity. Cyclotron uptime, batch success, release speed, and customer proximity directly affect usable dose supply.

Are FDG formulation patents commercially strong?

Basic formulation patents are generally less likely to create a durable barrier than patents covering a necessary synthesis route, purification method, automated manufacturing system, or specialized delivery technology.

References

1. National Institute of Standards and Technology. (n.d.). Radionuclide half-life data: Fluorine-18. U.S. Department of Commerce.

2. U.S. Food and Drug Administration. (n.d.). Fludeoxyglucose F 18 injection prescribing information. DailyMed.

3. United States Pharmacopeia. (2024). Fludeoxyglucose F 18 injection. In United States Pharmacopeia and National Formulary.

4. U.S. Food and Drug Administration. (2016). Current good manufacturing practice for PET drugs: Guidance for industry. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (n.d.). PET drugs: Regulatory information. Center for Drug Evaluation and Research.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.